Bank Of America Corp Aldeyra Therapeutics, Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 378,490 shares of ALDX stock, worth $2.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

378,490

Previous 398,951 5.13%

Holding current value

$2.02 Million

Previous $1.3 Million 3.99%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.25 - $4.72 $66,498 - $96,575	-20,461 Reduced 5.13%	378,490 $1.25 Million
Q1 2024 May 15, 2024	BUY	$2.77 - $4.22 $69,335 - $105,630	25,031 Added 6.69%	398,951 $1.3 Million
Q4 2023 Feb 14, 2024	BUY	$1.47 - $6.06 $113,547 - $468,092	77,243 Added 26.04%	373,920 $1.31 Million
Q2 2023 Aug 14, 2023	BUY	$7.11 - $11.89 $975,641 - $1.63 Million	137,221 Added 86.06%	296,677 $2.49 Million
Q1 2023 May 12, 2023	BUY	$5.77 - $9.93 $415,238 - $714,612	71,965 Added 82.25%	159,456 $1.58 Million
Q4 2022 Feb 10, 2023	SELL	$5.08 - $7.09 $96,596 - $134,816	-19,015 Reduced 17.85%	87,491 $608,000
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $99,191 - $202,037	-26,103 Reduced 19.68%	106,506 $568,000
Q2 2022 Aug 12, 2022	BUY	$2.43 - $4.85 $100,397 - $200,382	41,316 Added 45.26%	132,609 $529,000
Q1 2022 May 16, 2022	SELL	$3.25 - $5.17 $791,687 - $1.26 Million	-243,596 Reduced 72.74%	91,293 $406,000
Q4 2021 Feb 08, 2022	BUY	$3.5 - $9.63 $846,422 - $2.33 Million	241,835 Added 259.89%	334,889 $1.34 Million
Q3 2021 Nov 15, 2021	SELL	$7.94 - $11.31 $41,375 - $58,936	-5,211 Reduced 5.3%	93,054 $818,000
Q2 2021 Sep 13, 2021	BUY	$10.44 - $14.85 $1.03 Million - $1.46 Million	98,265 New	98,265 $1.11 Million

Others Institutions Holding ALDX

# of Institutions

106

Shares Held

35.1M

Call Options Held

153K

Put Options Held

83.9K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $311M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Aldeyra Therapeutics, Inc. Transaction History